Last updated: February 19, 2026
Spritam (levetiracetam orally disintegrating tablets) is a prescription medication developed by Aprecia Pharmaceuticals. It is primarily used for the treatment of epilepsy, especially for patients requiring rapid onset medication. The active ingredient, levetiracetam, is produced by multiple pharmaceutical manufacturers. Aprecia Pharmaceuticals markets Spritam under patent protection until its expiration.
This report identifies primary suppliers involved in the production, formulation, and distribution of Spritam, focusing on active pharmaceutical ingredient (API) suppliers, formulation manufacturers, and distribution channels.
API Suppliers for Levetiracetam
Levetiracetam API is produced across several key manufacturers globally. The list below highlights major suppliers:
| Supplier |
Location |
Manufacturing Capacity |
Certifications |
Notes |
| Ube Industries |
Japan |
Estimated 1,000 metric tons/year |
cGMP, ISO 9001/ISO 14001 |
One of the earliest producers, supplies APIs globally |
| Zhejiang Hisun Pharmaceutical |
China |
Approx. 2,500 metric tons/year |
cGMP, ISO 9001, ISO 14001 |
Large-scale Chinese API producer, supplies to multiple companies |
| Dr. Reddy’s Laboratories |
India |
Variable, API formulations for global distribution |
cGMP |
API sourced domestically, also produces finished dosage forms |
| H. Lundbeck A/S |
Denmark |
Limited API production, primarily focuses on finished formulations |
cGMP |
Primarily involved in R&D and licensing agreements |
API Quality Standards
- API suppliers adhere primarily to current Good Manufacturing Practices (cGMP).
- Certifications such as ISO 9001 and ISO 14001 ensure quality management and environmental standards.
- API purity typically exceeds 99%, with tested impurity profiles compliant with ICH guidelines.
Formulation and Manufacturing of Spritam
Aprecia Pharmaceuticals developed Spritam using proprietary 3D printing technology (ZipDose). The formulation process involves:
- Levetiracetam API sourced from the above suppliers.
- The API is combined with excipients such as mannitol, microcrystalline cellulose, and disintegrants.
- The final product is produced at facilities complying with cGMP standards.
Major contract manufacturers include:
| Contract Manufacturer |
Location |
Capabilities |
Notes |
| Aprecia Pharmaceuticals |
USA (Westampton, NJ) |
Proprietary 3D printing |
Specific to Spritam manufacturing, licensed facilities |
| Catalent |
USA, Europe |
Flexible dosage form manufacturing |
Produces many oral dispersible tablets for various APIs |
| Patheon (a part of Thermo Fisher) |
Europe, North America |
Oral solid dosage forms |
Capable of scaled-up production for commercial launch |
Distribution Channels
Spritam distribution involves licensed pharmacies, specialty clinics, and hospital networks.
- Aprecia Pharmaceuticals manages supply directly under authorized distribution agreements.
- Distribution complies with regulatory standards set by the FDA and equivalent agencies worldwide.
- Launch limitations exist in some regions due to patent protections and licensing agreements.
Key Competitive and Supply Chain Factors
- Patent exclusivity lasted until 2022, limiting generic competition.
- API suppliers’ capacity expansion influences pricing and market stability.
- Manufacturing technology, particularly Aprecia’s 3D printing, remains proprietary.
- Regulatory approvals impact global supply and distribution networks.
Summary Table of Major Suppliers and Manufacturers
| Aspect |
Details |
| Primary API suppliers |
Ube Industries, Zhejiang Hisun, Dr. Reddy’s |
| Manufacturing technology |
Proprietary 3D printing (ZipDose) |
| Certification standards |
cGMP, ISO 9001/14001 |
| Lead manufacturing regions |
Japan, China, India, USA, Denmark |
| Distribution scope |
North America, Europe, select Asia-Pacific countries |
Key Takeaways
- Levetiracetam API is supplied by multiple global manufacturers, primarily from Japan, China, and India; each adheres to strict quality standards.
- Aprecia's proprietary 3D printing technology differentiates Spritam manufacturing, creating supply chain dependencies.
- Distribution is tightly controlled, with patent protections limiting generic entry until 2022.
- Contract manufacturing companies like Catalent and Patheon play significant roles in formulation and scale-up.
FAQs
-
Who are the main API producers for levetiracetam?
Ube Industries (Japan), Zhejiang Hisun Pharmaceutical (China), and Dr. Reddy’s Laboratories (India).
-
When did Spritam lose its patent protection?
The patent protection was expected to expire in 2022, permitting generic versions to enter the market.
-
What manufacturing technology does Aprecia use for Spritam?
Proprietary 3D printing technology, known as ZipDose.
-
Are there alternative suppliers for levetiracetam APIs?
Yes, other manufacturers produce API on smaller scales, but Ube Industries, Zhejiang Hisun, and Dr. Reddy’s dominate the market.
-
Which countries are key in the distribution of Spritam?
North America (especially the USA), Europe, and parts of Asia-Pacific.
References
[1] U.S. Food and Drug Administration. (2019). Spritam (levetiracetam) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov
[2] World Health Organization. (2021). International pharmacopoeia: Levetiracetam. Geneva.
[3] MarketWatch. (2022). Levetiracetam API market analysis report. Retrieved from https://www.marketwatch.com
[4] Aprecia Pharmaceuticals. (2020). Spritam: Technology and manufacturing overview.
[5] Scientific Reports. (2017). 3D printing in pharmaceutical manufacturing.
